Zolmitriptan - AstraZeneca/Burroughs Wellcome
Alternative Names: 311-C90; 311C; AscoTop; BW-311C90; Zomig; Zomig-ZMT; ZomigonLatest Information Update: 05 Nov 2023
At a glance
- Originator Burroughs Wellcome
- Developer Amneal Pharmaceuticals; AstraZeneca
- Class Analgesics; Antimigraines; Indoles; Oxazolidinones; Small molecules; Tryptamines
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cluster headache; Menstrual migraine; Migraine
Most Recent Events
- 01 Oct 2022 IMPAX Laboratories in collaboration with AstraZeneca terminates phase III trial in Migraine due to slow enrollment (In Children) in USA (Intranasal) (NCT03275922)
- 06 Jan 2020 Zolmitriptan is still in phase III for Migraine (In children) in USA (Intranasal) (NCT03275922)
- 05 Dec 2018 Zolmitriptan licensed to Grunenthal for worldwide commercialisation excluding Japan for the treatment of acute migraines and cluster headaches before December 2018